Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$47.88 - $107.37
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $3.50B |
EV | $2.92B |
Shares Outstanding | 59.99M |
Beta | 0.33 |
Analyst Rating | BUY |
Analyst Target Price | $115.40 |
P/E 2025E | - |
P/Revenue 2025E | 39.20x |
Revenue | - |
EPS | 76.10% |
Operating Cash Flow | -15.50% |
Free Cash Flow | -41.10% |
Revenue | 29.80% |
EPS | -12.50% |
Operating Cash Flow | -3.20% |
Free Cash Flow | 11.60% |
Gross Margin 2025E | 100.00% |
Net Profit Margin 2025E | -187.16% |
ROE 2025E | -34.13% |
ROCE 2024 | -22.84% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Arcellx, Inc.
ACLX
Sector
Healthcare
Industry
Biotechnology
CEO
Elghandour, Rami
Employees
163
Website
www.arcellx.comIPO Date
2022-02-04
Headquarters
800 Bridge Parkway, Redwood City, California, 94065, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved